Trial Profile
Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Sickle Cell Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs BCL11a shRNA(miR) (Primary) ; Busulfan
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- 09 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 09 Jan 2023 Planned End Date changed from 13 Apr 2024 to 13 Nov 2024.
- 09 Jan 2023 Planned primary completion date changed from 13 Jun 2022 to 13 May 2024.